Hirschmann R
Department of Chemistry, University of Pennsylvania, Philadelphia 19104-6323.
Steroids. 1992 Dec;57(12):579-92. doi: 10.1016/0039-128x(92)90012-x.
The announcement in 1949, by Hench at the Mayo Clinic, that cortisone had a dramatic beneficial effect on bed-ridden patients suffering from rheumatoid arthritis ushered in the cortisone era. This medical landmark was made possible by the prior steroid research of distinguished chemists and biologists in several countries. The first partial synthesis of cortisone by Sarett was the culmination of a worldwide chemical effort. This work ultimately enabled the process research department at Merck, under the direction of Max Tishler, to perform the 37-step conversion of deoxycholic acid to cortisone on a scale that made the initial clinical trials possible. In spite of the enormity of the project, and the fact that neither of two closely related analogs of cortisone had shown any interesting biological activity. Merck elected to embark on this synthetically challenging project. The clinical results reported in 1949, combined with the complexity of the partial synthesis, stimulated highly innovative research to discover new routes to cortisone and to cortisol, the active hormone. This research, particularly in the pharmaceutical industry in the United States, Mexico, and Europe, demonstrated, among other things, the value of microbial transformations in synthetic sequences. The recognition that the chronic administration of cortisol produces several unexpected side effects stimulated an intensive effort in many countries to discover an analog with an improved therapeutic index. This led to more novel chemistry and many analogs were discovered that proved to be more potent than cortisol. Prednisolone, discovered at the Schering Corporation, was the first compound that combined a high level of anti-inflammatory activity with reduced salt retention. Derek Barton contributed greatly to steroid research during the 1950s by applying creative structural thinking to systematize a host of seemingly unrelated chemical and biological observations. The cortisone era had a profound impact on drug discovery also, since it led to the logical application of steric and electronic concepts to medicinal chemistry. Last, but not least, the cortisone era taught medicinal chemists many important lessons about drug-receptor interactions.
1949年,梅奥诊所的亨奇宣布,可的松对患类风湿性关节炎的卧床患者有显著疗效,由此开启了可的松时代。这一医学里程碑的实现得益于多个国家杰出化学家和生物学家此前的类固醇研究。萨雷特首次部分合成可的松是全球化学研究努力的成果。这项工作最终使默克公司的工艺研发部门在马克斯·蒂什勒的指导下,将脱氧胆酸转化为可的松的37步反应规模化,从而使初步临床试验成为可能。尽管该项目规模巨大,且可的松的两种密切相关类似物均未显示出任何有趣的生物活性,但默克公司仍选择着手这个合成难度极大的项目。1949年报告的临床结果,加上部分合成的复杂性,激发了极具创新性的研究,以探寻合成可的松及活性激素皮质醇的新途径。这项研究,尤其是在美国、墨西哥和欧洲的制药行业开展的研究,除其他成果外,还证明了微生物转化在合成序列中的价值。认识到长期服用皮质醇会产生一些意想不到的副作用,促使许多国家大力开展研究,以寻找治疗指数更高的类似物。这带来了更多新颖的化学方法,发现了许多比皮质醇更有效的类似物。先灵葆雅公司发现的泼尼松龙是首个兼具高抗炎活性和低盐潴留作用的化合物。20世纪50年代,德里克·巴顿通过运用创造性的结构思维,将一系列看似不相关的化学和生物学观察系统化,为类固醇研究做出了巨大贡献。可的松时代对药物发现也产生了深远影响,因为它促使人们将空间和电子概念合理应用于药物化学。最后但同样重要的是,可的松时代让药物化学家们在药物 - 受体相互作用方面学到了许多重要知识。